SCHEMBL692766

SCHEMBL692766

C=CCN(CC=C)C([O])=S

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.46
CYP1A2 P05177 1/20 0.39
SMN1; SMN2 Q16637 5/20 0.36
LMNA P02545 4/20 0.35
HPGD P15428 1/20 0.35
ALOX12 P18054 1/20 0.35
CCR6 P51684 1/20 0.35
KDM4E B2RXH2 4/20 0.33
HTT P42858 1/20 0.33
POLB P06746 2/20 0.32
MEN1 O00255 2/20 0.32
MAPT P10636 2/20 0.32
KMT2A Q03164 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
NPSR1 Q6W5P4 1/20 0.32
KCNH2 Q12809 1/20 0.32
PKM P14618 1/20 0.32
GAA P10253 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
NSD2 O96028 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4618339 0.77 ALDH1A1 (0.44) ALDH1A1CYP1A2SMN1; SMN2LMNAHPGD
SCHEMBL88004 0.74 ALDH1A1 (0.54) ALDH1A1CYP1A2SMN1; SMN2LMNAHPGD
SCHEMBL406319 0.74 CYP1A2 (0.45) ALDH1A1CYP1A2SMN1; SMN2LMNAHPGD
Hydrochloric Acid SCHEMBL11628599 0.72 CYP1A2 (0.44) ALDH1A1CYP1A2SMN1; SMN2LMNAHPGD
SCHEMBL1466473 0.72 ALDH1A1 (0.41) ALDH1A1CYP1A2SMN1; SMN2LMNAHPGD
SCHEMBL325008 0.72 ALDH1A1 (0.41) ALDH1A1CYP1A2SMN1; SMN2LMNAHPGD
SCHEMBL30903 0.72 HTT (0.43) ALDH1A1CYP1A2SMN1; SMN2LMNAHPGD
SCHEMBL692080 0.72 ALDH1A1 (0.52) ALDH1A1CYP1A2SMN1; SMN2LMNAHPGD
SCHEMBL2497205 0.72 ALDH1A1 (0.41) ALDH1A1CYP1A2SMN1; SMN2LMNAHPGD
SCHEMBL15887306 0.72 ALDH1A1 (0.41) ALDH1A1CYP1A2SMN1; SMN2LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1953148-B1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2012-02-29 EP claimed
US-7915267-B2 Heterocyclic amide compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-29 US claimed
US-20090137603-A1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-05-28 US claimed
EP-1953148-A1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2008-08-06 EP claimed
EP-1953148-B1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2012-02-29 EP disclosed
US-7915267-B2 Heterocyclic amide compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-29 US disclosed
US-20090137603-A1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-05-28 US disclosed
EP-1953148-A1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2008-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137603-A1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF MMP2, MMP9, MMP1 ALDH1A1 423/4885CYP1A2 471/4885SMN1; SMN2 3942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.